NCT07385638招募中2 期
Phase 2, Open-label Evaluation of Olorofim in Early Coccidioidal Meningitis
Fariba Donovan2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年6月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Safety: Number of participants with ≥1 treatment-emergent adverse event
研究概览
简要总结
This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study is exploratory, meaning that early information is being gathered to better understand the effectiveness of olorofim in coccidioidal meningitis in its early stages. The study plans to enroll approximately 10 to 12 participants who have been recently diagnosed-within the last 4 to 8 weeks-and who do not have a ventriculoperitoneal (VP) shunt, a medical device sometimes used to relieve pressure in the brain. Participants will be followed for approximately 6 months, during which health information will be collected to evaluate disease progression and response to treatment. Participants may have the opportunity to enroll in the olorofim Managed Access Program to continue treatment after completion of the study period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients aged ≥ 18 years and weighing ≥ 40 kg, able to understand and consent in English, who have been fully informed and:
- •a) who have given voluntary written informed consent, or whose legally authorized representative(s) has been fully informed and has given voluntary written informed consent if applicable, and in compliance with local regulations OR
- •b) who have given oral informed consent witnessed in writing by an independent person and in compliance with local regulations for patients who are unable to write and/or read but who fully understand the oral information given by the Investigator (or nominated representative).
- •Ongoing coccidioidomycotic meningitis diagnosed within 8 weeks prior to enrolment.
- •Ongoing symptoms due to coccidioidomycosis are such that the risk-benefit of treatment with an investigational agent with a hepatic signal requiring careful monitoring is judged favorable based on meeting criteria
- •Female patients must be non-lactating and at no risk of pregnancy for one of the following reasons:
- •Postmenopausal for at least 1 year;
- •Post-hysterectomy and/or post-bilateral oophorectomy;
- •Of childbearing potential, with a negative urine or serum human chorionic gonadotropin pregnancy test at the screening visit and must be using one of listed below highly effective method of birth control throughout the course of the study period and up to and including 30 days after stopping study drug
- •Established use of oral, injected, transdermal, intravaginal, or implanted hormonal methods of contraception associated with inhibition of ovulation
- •Placement of an intrauterine device or intrauterine hormone-releasing system
- •Male sterilization
- •Bilateral tubal occlusion
- •Sexual abstinence (reliable sexual abstinence is acceptable but periodic abstinence [e.g., calendar, ovulation, symptom-thermal, or post-ovulation methods] and withdrawal are not acceptable).
- •Male patients with female partners of childbearing potential must either totally abstain from sexual intercourse or use a highly effective means of contraception throughout study participation and agree to continue its use for 30 days after stopping study drug and may not donate semen during this time.
排除标准
- •Patients who are unconscious.
- •Patients who are pregnant or breastfeeding.
- •Known history of allergy, hypersensitivity, or any serious reaction to any component of the olorofim.
- •Patients with or planned placement of indwelling CNS hardware (e.g. reservoirs, shunts, ventriculostomies, or external drainage tubes).
- •Patients with a second fungal infection requiring systemic antifungal treatment or prophylaxis, other than Pneumocystis jirovecii infections and cutaneous fungal infections treated topically.
- •Patients with microbiological findings (e.g., bacteriological, virological) or other potential conditions that are temporally related and suggest a different than study indication etiology.
- •HIV infection but not currently receiving antiretroviral therapy. In cases where HIV infection is first diagnosed at the same time as the invasive fungal infection, if antiretroviral therapy is commenced at the time of enrollment, then such patients are eligible for enrolment
- •Any known or suspected medical condition or social circumstance of the patient that may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy.
- •Patients with a concomitant medical condition that, in the opinion of the Investigator, may be an unacceptable additional risk to the patient should he/she participate in the study.
- •Patients who have received prior treatment with olorofim/F
- •Treatment with any investigational drug within the 30 days prior to the first administration of study drug except for unblinded protocols (eg, open-label oncological regimen variations or biologic studies). Prior to enrolling patients who are on other open-label studies, it is the site's responsibility to ensure that the study criteria for that study allow for enrollment into this study.
- •Patients receiving treatment limited to supportive care due to predicted short survival time.
- •Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation, eg,
- •A family history of long QT syndrome
- •Other known pro-arrhythmic conditions
- •Risk factors for Torsade de Pointes (e.g., uncompensated heart failure, abnormal plasma potassium or magnesium levels that cannot be corrected, an unstable cardiac condition during the last 30 days).
- •Evidence of hepatic dysfunction with any of the following abnormal laboratory parameters at screening:
- •Total bilirubin ≥ 2 × upper limit of the normal range (ULN), OR
- •Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 × ULN, OR
- •Patients with known cirrhosis or chronic hepatic failure (regardless of ALT/AST/total bilirubin).
- •Liver transplant recipients may be enrolled if their laboratory parameters do not meet the laboratory exclusions given above.
- •Prohibited concomitant medications. Concomitant administration of inhibitors of human dihydro-orotate dehydrogenase (DHODH), teriflunomide, leflunomide, and systemic use of cannabis/cannabinoid preparations, including tetrahydrocannabinol (THC) and cannabidiol (CBD) are prohibited. There are currently no other absolutely prohibited concomitant medications for olorofim but there are medications with potentially significant drug-drug interactions (DDIs) with olorofim or SOC and the management of potential interactions should be considered before study enrollment.
研究组 & 干预措施
olorofim
Experimental
Participants will receive treatment with olorofim
干预措施: olorofim (Drug)
结局指标
主要结局
Safety: Number of participants with ≥1 treatment-emergent adverse event
时间窗: First dose through end of treatment and 4-week follow-up
Counts and proportions of participants experiencing at least one adverse event after initiation of olorofim, regardless of causality. Adverse events will be coded and graded according to CTCAE v5.0.
次要结局
- Efficacy: Investigator-assessed clinical response over 24 weeks(Baseline through Week 24 (End of Treatment))
- Efficacy: Change from baseline in Coccidioides serum complement fixation titers(Baseline through Week 24)
- Efficacy: Radiological response assessed by imaging(Baseline through Week 24)
- Efficacy: Investigator-assessed overall treatment response(Baseline through Week 24)
- Efficacy: All-cause mortality(Baseline through Week 24 and 4-week follow-up)
- Patient-reported Outcome: Change from baseline in Modified Zubrod Performance Score(Baseline through Week 24)
- Patient-reported Outcome: Change from baseline in Valley Fever Patient-Reported Outcomes (VF-PRO) score(Baseline through Week 24)
- Patient-reported Outcome: Change from baseline in Clinical Global Impression-Severity (CGI-S) and Patient Global Impression-Severity (PGI-S)(Baseline through Week 24)
- ECG Sub-Study: Change from baseline in QTcF interval(Day 10-21 (single study day))
研究者
Fariba Donovan
MD, PhD
University of Arizona
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot StudyAtopic DermatitisNCT07297602Nora Mohamed Abdelrazik36
招募中
2 期
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT07365306City of Hope Medical Center43
已完成
1 期
Impact of Clinician-administered Vaginal Live Biotherapeutic ProductBacterial VaginosisNCT07305844Caroline Mitchell26
尚未招募
2 期
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.NCT07353268Tao Zhang76
招募中
1 期
This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms2023-504795-20-00AbbVie Deutschland GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG6